マサチューセッツ州における自己免疫疾患の臨床試験
マサチューセッツ州内の拠点で、自己免疫疾患に関する16件の研究が参加者を募集しています。
マサチューセッツ州内の都市
公式研究テキスト（英語）
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
- Tufts Medical Center, Boston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07621809Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/23更新 · NCT03816345A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Massachusetts General Hospital, Boston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/18更新 · NCT06722235RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- Boston Children's Hospital - Accepting Young Adults and Juvenile Patients, Boston
被験者募集中第2/3相
6歳〜75歳 · 全性別 · 2026/09/17更新 · NCT06154252A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Massachusetts General Hospital, Boston
- University of Massachusetts Chan Medical School, Worcester
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06948318The Mycophenolate Pregnancy Registry
- Quintiles Outcome, Cambridge
被験者募集中観察研究
全年齢 · 女性 · 2026/09/08更新 · NCT01733082RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Boston Children's Hospital, Boston
- 他2件
被験者募集中第1/2相
18歳〜65歳 · 全性別 · 2026/08/26更新 · NCT06121297Prednisone in Adults With an Immune-Mediated Subtype of Autism Spectrum Disorder
- MGH Lurie Center for Autism, Lexington
被験者募集中早期第1相
18歳〜50歳 · 男性 · 2026/08/19更新 · NCT06934915RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
- Beth Israel Deaconess Medical Center, Boston
- University of Massachusetts Chan Medical School, Worcester
被験者募集中第1/2相
18歳〜70歳 · 全性別 · 2026/08/13更新 · NCT06359041A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
- Boston Children's Cancer Center, Boston
被験者募集中第3相
12歳以上 · 全性別 · 2026/08/06更新 · NCT06056297Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1049, Foxborough
被験者募集中第3相
18歳〜80歳 · 全性別 · 2026/07/30更新 · NCT07039916A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
- Brigham And Womens Hospital, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/14更新 · NCT07115745A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中観察研究
全年齢 · 全性別 · 2026/07/06更新 · NCT01351545Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
- Tufts University, Boston
- Massachusetts General Hospital, Boston
- Brigham and Women's Hospital, Boston
被験者募集中第1相
18歳〜70歳 · 全性別 · 2026/06/30更新 · NCT06201416A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- Brigham and Women's Hospital, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/05/29更新 · NCT04422912Testimonials and Navigation in Rheumatology
- Brigham Women's Hospital, Boston
- University of Massachusetts Chan Medical School, Worcester
被験者募集中
18歳以上 · 全性別 · 2026/05/06更新 · NCT06469788ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。